Seebri Breezhaler is a treatment for the symptoms of Chronic Obstructive Pulmonary Disease (COPD).
Talk to us about your health and we’ll recommend the best treatment for you. Order Seebri Breezhaler online on a subscription that you can cancel whenever you like.
Once-daily glycopyrronium bromide (Seebri Breezhaler®) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy, 16(17), pp.2653–2659.
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. International Journal of Chronic Obstructive Pulmonary Disease, p.1233.
We know health, but you know you.
Our experts tell you what’s safe, but you decide what’s best.
Answer a few questions and tell us about yourself. Get tailored advice from our clinicians so you can choose better.
Choose your treatment and how often you have it delivered.
We know things change. It’s the nature of life. We’ll check in regularly to make sure your treatment is still right for you.
Pause. Change. Skip. Start again. Any time you like.
COPD: Here are some other options.
Once-a-day inhaler that relaxes muscles in your lungs, to treat symptoms of COPD.
CFC-free pressurised inhaler. Bronchodilator for use throughout the day.
Breaks down mucus – making it easier to clear when you cough. Two capsules, three times a day.
Nebuliser with two ingredients to help you breathe easier.
Bronchodilator that provides twenty-four-hour COPD relief. Combines an LABA with an anticholinergic.
Eases symptoms and stops COPD getting worse. Powder or capsule options.
Powder inhaler with three active ingredients to improve COPD.
Combination relief and prevention for COPD symptoms, in an MDI or NEXThaler.
If there’s a particular treatment or condition you’re looking for, tell us and we’ll look into it for you.
Submit your question here, or tell us if you’ve found an issue on our site.
We’ll get back to you very soon. We aim to respond to all queries in one working day.
You’re signed up to our newsletter. Keep an eye on your inbox for our latest update.